Trial Tokenization Workshop for Life Sciences
HOSTED BY DATAVANT
March 7, 2023 12:00 to 6:30PM
Boston Museum of Science, Skyline Room
OVERVIEW
Datavant is convening leaders from our life sciences customers to talk about tokenization and linking real-world data in clinical trials. This is an opportunity to learn from your peers and discuss openly how your organization is approaching trial tokenization, including obstacles and breakthroughs. We will go deep on use cases, tactics, and best practices for successfully implementing tokenization solutions in clinical studies.
ATTENDEES
Clinical development, innovation, and real-world data leaders from the life sciences industry
LOCATION AND DATE
March 7, 2023
Boston Museum of Science, The Skyline Room
1 Museum of Science Driveway
Boston, MA 02114
Agenda
12:00 to 12:30PM: Lunch & Registration
12:30 to 1:15PM: Introductions & Purpose
1:15 to 1:45PM: Update on Datavant Trials
1:45 to 2:00PM: Break
2:00 to 2:30PM: Engaging Trials Stakeholders Across Companies, Partner, and Sites
2:30 to 3:00PM: Lessons from the Front Lines on Site Engagement, Consent, and Technology
3:00 to 3:30PM: Linked Data Acceleration Opportunities Featuring the Broad Institute of MIT and Harvard
3:45 to 4:30PM: Breakout Sessions
4:30 to 4:35PM: Closing Remarks
4:30 to 6:30PM: Happy Hour
SNAPSHOT
The Tokenization Workshop will be hosted at the Boston Museum of Science on the second floor in The Skyline Room. There is complimentary parking available on site, please make sure to bring your parking ticket with you to have it validated.
If you have any dietary restrictions please reach out to events@datavant.com to ensure there are options available for you. If you have any logistical issues with finding the venue day of, please reach out to Ritida Nanda on our marketing team by calling or texting (925) 640 7774.

New York Trial Tokenization Workshop Recap
Our last Trials Tokenization Workshop was at the Standard High Line in New York City. We had approximately 35 attendees from 17 different life science companies. We discussed the value of tokenizing clinical trials, lessons from the field in managing trial sites, and the evolving real-world data and regulatory landscape.


